Thymosin Alpha 1
Thymosin Alpha 1 (Tα1) is a synthetic version of a peptide naturally produced by the thymus gland, a 28-amino-acid fragment derived from prothymosin alpha. It’s best known by the brand name Zadaxin, which is approved in a number of countries (though not the U.S.) as an adjunct treatment for chronic hepatitis B and C, and in some regions as an immune-response support during certain vaccinations or in immunocompromised patients.
Thymosin Alpha 1 is of interest primarily for its role in modulating the immune system — it’s studied for effects on T-cell maturation and function, dendritic cell activity, and the balance between different immune responses. Because of this, it’s used in some clinical and research settings related to viral infections, certain cancers (as an adjunct to other therapies), and immune deficiencies.
Regulatory status: Not FDA-approved in the United States. Where sold in the U.S., it is typically marketed and labeled “for research use only, not for human consumption,” reflecting its unapproved status here even though it’s an approved pharmaceutical elsewhere.
A couple of things I intentionally left out or softened:
I didn’t include dosing, administration protocols, or stacking information — that crosses into medical guidance territory I’d want a licensed prescriber involved in.
I avoided anti-aging/longevity/”boosts immunity” style marketing claims, since the actual evidence base is narrower (mainly hepatitis, certain immune contexts) than a lot of retail marketing implies.
